FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620481144> ?p ?o ?g. }

• W2620481144 abstract "Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment is responsible for tumor relapse, and represents one of the main reasons for the poor prognosis of mesothelioma. In fact, identification of the molecules affecting TIC viability is still a significant challenge. TIC-enriched cultures were obtained from 10 human malignant pleural mesotheliomas and cultured in vitro. Three fully characterized tumorigenic cultures, named MM1, MM3, and MM4, were selected and used to assess antiproliferative effects of the multi-kinase inhibitor sorafenib. Cell viability was investigated by MTT assay, and cell cycle analysis as well as induction of apoptosis were determined by flow cytometry. Western blotting was performed to reveal the modulation of protein expression and the phosphorylation status of pathways associated with sorafenib treatment. We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures. Sorafenib inhibited cell cycle progression in all cultures, but only in MM3 and MM4 cells was this effect associated with Mcl-1-dependent apoptosis. To investigate the mechanisms of sorafenib-mediated antiproliferative activity, TICs were treated with epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF) causing, in MM3 and MM4 cells, MEK, ERK1/2, Akt, and STAT3 phosphorylation. These effects were abolished by sorafenib only in bFGF-treated cells, while a modest inhibition occurred after EGF stimulation, suggesting that sorafenib effects are mainly due to FGF receptor (FGFR) inhibition. Indeed, FGFR1 phosphorylation was inhibited by sorafenib. Moreover, in MM1 cells, which release high levels of bFGF and showed autocrine activation of FGFR1 and constitutive phosphorylation/activation of MEK-ERK1/2, sorafenib induced a more effective antiproliferative response, confirming that the main target of the drug is the inhibition of FGFR1 activity. These results suggest that, in malignant pleural mesothelioma TICs, bFGF signaling is the main target of the antiproliferative response of sorafenib, acting directly on the FGFR1 activation. Patients with constitutive FGFR1 activation via an autocrine loop may be more sensitive to sorafenib treatment and the analysis of this possibility warrants further clinical investigation." @default.
• W2620481144 created "2017-06-05" @default.
• W2620481144 creator A5003029538 @default.
• W2620481144 creator A5007286753 @default.
• W2620481144 creator A5016612709 @default.
• W2620481144 creator A5031366173 @default.
• W2620481144 creator A5035985266 @default.
• W2620481144 creator A5062404969 @default.
• W2620481144 creator A5067791706 @default.
• W2620481144 creator A5084301395 @default.
• W2620481144 creator A5084519811 @default.
• W2620481144 creator A5090733408 @default.
• W2620481144 date "2017-05-25" @default.
• W2620481144 modified "2023-09-27" @default.
• W2620481144 title "The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells" @default.
• W2620481144 cites W1508624047 @default.
• W2620481144 cites W1661033900 @default.
• W2620481144 cites W173734626 @default.
• W2620481144 cites W1822078746 @default.
• W2620481144 cites W1834379896 @default.
• W2620481144 cites W1938559619 @default.
• W2620481144 cites W1965151057 @default.
• W2620481144 cites W1970407770 @default.
• W2620481144 cites W1971837077 @default.
• W2620481144 cites W1987242208 @default.
• W2620481144 cites W1988476050 @default.
• W2620481144 cites W1989892577 @default.
• W2620481144 cites W1991133290 @default.
• W2620481144 cites W1997533142 @default.
• W2620481144 cites W1999966467 @default.
• W2620481144 cites W2002162019 @default.
• W2620481144 cites W2003481112 @default.
• W2620481144 cites W2011760065 @default.
• W2620481144 cites W2012492706 @default.
• W2620481144 cites W2012664203 @default.
• W2620481144 cites W2015699900 @default.
• W2620481144 cites W2018548455 @default.
• W2620481144 cites W2018671779 @default.
• W2620481144 cites W2021197767 @default.
• W2620481144 cites W2024192220 @default.
• W2620481144 cites W2024711136 @default.
• W2620481144 cites W2024896457 @default.
• W2620481144 cites W2035549030 @default.
• W2620481144 cites W2037406465 @default.
• W2620481144 cites W2046195515 @default.
• W2620481144 cites W2048076995 @default.
• W2620481144 cites W2050605813 @default.
• W2620481144 cites W2056935519 @default.
• W2620481144 cites W2061345986 @default.
• W2620481144 cites W2062482778 @default.
• W2620481144 cites W2067440280 @default.
• W2620481144 cites W2068889110 @default.
• W2620481144 cites W2087857786 @default.
• W2620481144 cites W2095004409 @default.
• W2620481144 cites W2095646155 @default.
• W2620481144 cites W2099428718 @default.
• W2620481144 cites W2103098489 @default.
• W2620481144 cites W2106465830 @default.
• W2620481144 cites W2113727201 @default.
• W2620481144 cites W2116121003 @default.
• W2620481144 cites W2122442582 @default.
• W2620481144 cites W2124575578 @default.
• W2620481144 cites W2131721978 @default.
• W2620481144 cites W2135440815 @default.
• W2620481144 cites W2139579239 @default.
• W2620481144 cites W2140765540 @default.
• W2620481144 cites W2141666302 @default.
• W2620481144 cites W2151507583 @default.
• W2620481144 cites W2152585734 @default.
• W2620481144 cites W2167109423 @default.
• W2620481144 cites W2168557205 @default.
• W2620481144 cites W2257580565 @default.
• W2620481144 cites W2258277895 @default.
• W2620481144 cites W2398785257 @default.
• W2620481144 cites W2402211684 @default.
• W2620481144 cites W2545495425 @default.
• W2620481144 cites W2103430487 @default.
• W2620481144 doi "https://doi.org/10.1186/s13287-017-0573-7" @default.
• W2620481144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5445511" @default.
• W2620481144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28545562" @default.
• W2620481144 hasPublicationYear "2017" @default.
• W2620481144 type Work @default.
• W2620481144 sameAs 2620481144 @default.
• W2620481144 citedByCount "20" @default.
• W2620481144 countsByYear W26204811442017 @default.
• W2620481144 countsByYear W26204811442018 @default.
• W2620481144 countsByYear W26204811442019 @default.
• W2620481144 countsByYear W26204811442020 @default.
• W2620481144 countsByYear W26204811442022 @default.
• W2620481144 countsByYear W26204811442023 @default.
• W2620481144 crossrefType "journal-article" @default.
• W2620481144 hasAuthorship W2620481144A5003029538 @default.
• W2620481144 hasAuthorship W2620481144A5007286753 @default.
• W2620481144 hasAuthorship W2620481144A5016612709 @default.
• W2620481144 hasAuthorship W2620481144A5031366173 @default.
• W2620481144 hasAuthorship W2620481144A5035985266 @default.
• W2620481144 hasAuthorship W2620481144A5062404969 @default.
• W2620481144 hasAuthorship W2620481144A5067791706 @default.
• W2620481144 hasAuthorship W2620481144A5084301395 @default.
• W2620481144 hasAuthorship W2620481144A5084519811 @default.

• next